Podcasts about movement disorders center

Essential tremor is the most common movement disorder, although it is often misdiagnosed. A careful history and clinical examination for other neurologic findings, such as bradykinesia, dystonia, or evidence of peripheral neuropathy, can reveal potential alternative etiologies. Knowledge about epidemiology and associated health outcomes is important for counseling and monitoring for physical impairment and disability. In this episode, Lyell Jones, MD, FAAN, speaks with Ludy C. Shih, MD, MMSc, FAAN, author of the article “Essential Tremor” in the Continuum® August 2025 Movement Disorders issue. Dr. Jones is the editor-in-chief of Continuum: Lifelong Learning in Neurology® and is a professor of neurology at Mayo Clinic in Rochester, Minnesota. Dr. Shih is clinical director of the Parkinson's Disease and Movement Disorders Center at Beth Israel Deaconess Medical Center in Boston, Massachusetts. Additional Resources Read the article: Essential Tremor Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @LyellJ Guest: @ludyshihmd Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum: Lifelong Learning in Neurology. Today, I'm interviewing Dr Ludy Shih, who recently authored an article on essential tremor for our latest issue of Continuum on movement disorders. Dr Shih is an associate professor of neurology at Harvard Medical School and the clinical director of the Parkinson's Disease and Movement Disorder Center at Beth Israel Deaconess Medical Center in Boston. Dr Shih, welcome, and thank you for joining us today. Why don't you introduce yourself to our listeners? Dr Shih: Thank you, Dr Jones, for having me. It's a real pleasure to be here on the podcast with you. I'm a neurologist, I trained in movement disorders fellowship, and I currently see patients and conduct clinical research. We offer a variety of treatments and diagnostic tests for our patients with movement disorders. And I have developed this interest, a clinical research interest in essential tremor. Dr Jones: And so, as an expert in essential tremor, the perfect person to write such a really spectacular article. And I can't wait for our listeners to hear more about it and our subscribers to read it. And let's get right to it. If you had, Dr Shih, a single most important message for our listeners about caring for patients with essential tremor, what would that message be? Dr Shih: Yeah, I think the takeaway that I've learned over the years is that people with essential tremor do develop quite a few other symptoms. And although we propose that essential tremor is this pure tremor disorder, they can experience a lot of different comorbidities. Now, there is some debate as to whether that is expected for essential tremor or is this some part of another syndrome, which we may talk about later in the interview. But the fact of the matter is, it's not a benign condition and people do experience some disability from it. Dr Jones: And I think that speaks to how the name of this disorder has evolved over time. right? You point out in your article, it used to be called benign essential tremor or benign familial tremor. But it's really not so straightforward as it. And fairly frequently these symptoms, the patient's tremor, can be functionally limiting, correct? Dr Shih: That is correct. In fact, the reason I probably started getting interested in essential tremor was because our center had been doing a lot of deep brain stimulation for essential tremor, which is remarkably effective, especially for tremor that reaches an amplitude that really no oral medication is going to satisfyingly treat. And if you have enough upper limb disability from this very large-amplitude tremor, a surgical option may make a lot of sense for a lot of patients. And yet, how did they get to that point? Do they continue to progress? These were the sort of interesting questions that got raised in my mind as I started to treat these folks. Dr Jones: We'll come back to treatment in just a minute here, because there are many options, and it sounds like the options are expanding. To start with the diagnosis- I mean, this is an extraordinarily common disorder. As you point out, it is the most common movement disorder in the US and maybe the world, and yet it seems to be underrecognized and frequently misdiagnosed. Why do you think that is? Dr Shih: Great question. It's been pretty consistent, with several case series over the decades showing a fairly high rate of quote/unquote “misdiagnosis.” And I think it speaks to two things, probably. One is that once someone sees a postural and kinetic tremor of the arms, immediately they think of essential tremor because it is quite common. But there's a whole host of things that it could actually be. And the biggest one that we also have to factor in is also the heterogeneity of the presentation of Parkinson's disease. Many people, and I think increasingly now these days, can present with not a whole lot of the other symptoms, but may present with an atypical tremor. And it becomes actually a little hard to sort out, well, do they have enough of these other symptoms for me to suspect Parkinson's, or is the nature of their tremor suspicious enough that it would just be so unusual that this stays essential tremor and doesn't eventually develop into Parkinson's disease? And I think those are the questions that we all still grapple with from time to time in some of our clinics. Dr Jones: Probably some other things related to it with, you know, our understanding of the pathophysiology and the availability of tests. And I do want to come back to those questions here in just a minute, but, you know, just the nomenclature of this disorder… I think our clinical listeners are familiar with our tendency in medicine to use words like essential or idiopathic to describe disorders or phenomena where we don't understand the precise underlying mechanism. When I'm working with our trainees, I call these “job-security terms” because it sounds less humbling than “you have a tremor and we don't know what causes it,” right? So, your article does a really nice job outlining the absence of a clear monogenic or Mendelian mechanism for essential tremor. Do you think we'll ever have a eureka moment in neurology for this disorder and maybe give it a different name? Dr Shih: It's a great question. I think as we're learning with a lot of our neurologic diseases---and including, I would even say, Parkinson's disease, to which ET gets compared to a lot---there's already now so much more known complexity to something that has a very specific idea and concept in people's minds. So, I tend to think we'll still be in an area where we'll have a lot of different causes of tremor, but I'm hopeful that we'll uncover some new mechanisms for which treating or addressing that mechanism would take care of the tremor in a way that we haven't been able to make as much progress on in the last few decades as maybe we would have thought given all the advances in in technology. Dr Jones: That's very helpful, and we'll be hopeful for that series of discoveries that lead us to that point. I think many of our listeners will be familiar with the utility---and, I think, even for most insurance companies, approval---for DAT scans to discriminate between essential tremor and Parkinsonian disorders. What about lab work? Are there any other disorders that you commonly screen for in patients who you suspect may have essential tremor? Dr Shih: Yeah, it's a great question. And I think, you know, I'm always mindful that what I'm seeing in my clinic may not always be representative of what's seen in the community or out in practice. I'll give an example. You know, most of the time when people come to the academic Medical Center, they're thinking, gosh, I've tried this or that. I've been on these medicines for the last ten years. But I've had essential tremor for twenty years. We get to benefit a little bit from all that history that's been laid down. And so, it's not as likely you're going to misdiagnose it. But once in a while, you'll get someone with tremor that just started a month ago or just started, you know, 2 or 3 months ago. And you have to still be thinking, well, I've got to get out of the specialist clinic mindset, and think, well, what else really could this be? And so, while it's true for everybody, moreso in those cases, in those recent onset cases, you really got to be looking for things like medications, electrolyte abnormalities, and new-onset thyroid disorder, for example, thyroid toxicosis. Dr Jones: Very helpful. And your article has a wonderful list of the conditions to consider, including the medications that might be used for those conditions that might result or unmask a tremor of a different cause. And I think being open-minded and not anchoring on essential tremor just because it's common, I think is a is a key point here. And another feature in your article that I really enjoyed was your step-by-step approach to tremor. What are those steps? Dr Shih: Well, I think you know first of all, tremor is such common terminology that even lay people, patients, nonclinicians will use the word “tremor.” And so, it can be tempting when the notes on your schedule says referred for tremor to sort of immediately jump to that. I think the first step is, is it tremor? And that's really something that the clinician first has to decide. And I think that's a really important step. A lot of things can look superficially like tremor, and you shouldn't even assume that another clinician knows what tremor looks like as opposed to, say, myoclonus. Or for example a tremor of the mouth; well, it actually could be orolingual or orobuccal dyskinesia, as in tardive dyskinesia. And another one that tremor can look like is ataxia. And so, I think- while they sound obvious to most neurologists, perhaps, I think that---especially in the area of myoclonus, where it can be quite repetitive, quite small amplitude in some conditions---it can really resemble a tremor. And so, there are examples of these where making that first decision of whether it's a tremor or not can really be a good sort of time-out to make sure you're going down the right path to begin with. And I think what's helpful is to think about some of the clinical definitions of a tremor. And tremor is really rhythmic, it's oscillatory. You should see an agonist and antagonist muscle group moving back and forth, to and fro. And then it's involuntary. And so, I think these descriptors can really help; and to help isolate, if you can describe it in your note, you can probably be more convinced that you're dealing with the tremor. The second step that I would encourage people to really consider: you've established it's a tremor. The most important part exam now becomes, really, the nontremor part of the exam. And it should be really comprehensive to think of what else could be accompanying this, because that's really how we make diagnosis of other things besides essential tremor. There really should be a minimum of evidence of parkinsonism, dystonia, neuropathy, ataxia- and the ataxia could be either from a peripheral or central nervous system etiology. Those are the big four or five things that, you know, I'm very keen to look for and will look pretty much in the head, neck, the axial sort of musculature, as well as the limbs. And I think this is very helpful in terms of identifying cases which turn out to have either, say, well, Parkinson's or even a typical Parkinson disorder; or even a genetic disorder, maybe even something like a fragile X tremor ataxia syndrome; or even a spinal cerebellar ataxia. These cases are rare, but I think if you uncover just enough ataxia, for example, that really shouldn't be there in a person, let's say, who's younger and also doesn't have a long history of tremor; you should be more suspicious that this is not essential tremor that you're dealing with. And then the last thing is, once you've identified the tremor and you're trying to establish, well, what should be done about the tremor, you really have to say what kind of tremor it is so that you can follow it, so you can convey to other people really what the disability is coming from the tremor and how severe the tremor is. So, I think an example of this is, often in the clinic, people will have their patients extend their arms and hands and kind of say, oh, it's an essential tremor, and that's kind of the end of the exam. But it doesn't give you the flavor. Sometimes you'll have a patient come in and have a fairly minimal postural tremor, but then you go out, take those extra few seconds to go grab a cup of water or two cups of water and have them pour or drink. And now all of a sudden you see this tremor is quite large-amplitude and very disabling. Now you have a better appreciation of what you really need to do for this patient, and it might not be present with just these very simple maneuvers that you have at bedside without props and items. And then the severity of it; you know, we're so used to saying mild, moderate, severe. I think what we've done in the Tremor Research Group to use and develop the Essential Tremor Rating Assessment Scale is to get people used to trying to estimate what size the tremor is. And you can do that by taking a ruler or developing a sense of what 1 centimeter, 2 centimeters, 3 centimeters looks like. I think it'd be tremendously helpful too, it's very easy and quick to convey severity in a given patient. Dr Jones: I appreciate you, you know, having a patient-centered approach to the- how this is affecting them and being quantitative in the assessment of the tremor. And that's a great segue to a key question that I run into and I think others run into, which is when to initiate therapy? You know, if you see a patient who, let's say they have a mild tremor or, you know, something that quantitatively is on the mild end of the spectrum, and you have, you know, a series of options… from a medication perspective, you have to say, well, when does this across that threshold of being more likely to benefit the patient than to harm the patient? How do you approach that question? What's your threshold for starting medication? Dr Shih: Yeah. You know, sometimes I will ask, because---and I know this sounds like a strange question---because I feel like my patients will come for a couple of different reasons. Sometimes it's usually one over the other. I think people can get concerned about a symptom of a tremor. So, I actually will ask them, was your goal to just get a sense for what this tremor is caused by? I understand that many people who develop tremor might be concerned it might be something like Parkinson's disease. Or is this also a tremor that is bothering you in day-to-day life? And often you will hear the former. No, I just wanted to get checked out and make sure you don't think it's Parkinson's. It doesn't bother me enough that I want to take medication. They're quite happy with that. And then the second scenario is more the, yeah, no, it bothers me and it's embarrassing. And that's a very common answer you may hear, may be embarrassing, people are noticing. It's funny in that many people with essential tremor don't come to see a doctor or even the neurologist for many years. And they will put up with it for a very long time. And they've adopted all sorts of compensatory strategies, and they've just been able to handle themselves very admirably with this, in some cases, very severe tremor. So, for some of them, it'll take a lot to come to the doctor, and then it becomes clear. They said, I think I'm at the point where I need to do something about this tremor. And so, I think those three buckets are often sort of where my patients fall into. And I think asking them directly will give you a sense of that. But you know, it can be a nice time to try some as-needed doses of something like Propranolol, or if it's something that you know that they're going to need something on day-to-day to get control of the tremor over time, there are other options for that as well. Dr Jones: Seems like a perfect scenario for shared decision-making. Is it bothersome enough to the patient to try the therapy? And I like that suggestion. That's a nice pearl that you could start with an a- needed beta blocker, right, with Propranolol. And this is a question that I think many of us struggle with as well. If you've followed a patient with essential tremor for some time and you've tried different medications and they've either lost effectiveness or have intolerable adverse effects, what is your threshold for referring a patient for at least considering a surgical neurostimulator therapy for their essential tremor? Dr Shih: Yeah, so surgical therapies for tremor have been around for a long time now, since 1997, which was when it was approved by the FDA for essential tremor and Parkinson tremor. And then obviously since then, we have a couple more options in the focus ultrasound thalamotomy, which is a lesioning technique. When you have been on several tremor medications, the list gets smaller and smaller. It- and then chance of likely satisfying benefit from some of these medications can be small and small as you pass through the first and second line agents and these would be the Propranolol and the primidone. And as you say, quite a few patients- it's estimated between 30 to 50% of these patients end up not tolerating these first two medications and end up discontinuing them. Some portion of that might also be due to the fact that some of our patients who have been living with essential tremor for decades now, to the point that their tremor is getting worse, are also getting older. And so, polypharmacy and/or some of the potential side effects of beta blockers and anticonvulsants like primidone may be harder to bear in an older adult. And then as you talk about in the article, there's some level of evidence for topiramate, and then from there a number of anticonvulsants or benzos, which have even weaker evidence for them. It's a personal decision. As I tell folks, look, this is not going to likely extend your life or save your life, but it's a quality of life issue. And of course, if there are other things going on in life that need to be taken care of and they need that kind of care and attention, then, you know, you don't need to be adding this to your plate. But if you are in the position where those other things are actually okay, but quality of life is really affected by your being unable to use your upper limbs in the way that you would like to… A lot of people's hobbies and applications are upper limb-based, and enjoying those things is really important. Then I think that this is something- a conversation that we begin and we begin by talking about yes, there are some risks involved, but fortunately this is the data we have on it, which is a fairly extensive experience in terms of this is the risk of, you know, surgery-related side effects. This is the risk of if you're having stimulation from DBS stimulation-related side effects, which can be adjustable. It's interesting, I was talking with colleagues, you know, after focused ultrasound thalamotomy was approved. That really led more people to come to the clinic and start having these discussions, because that seemed like a very the different sort of approach where hardware wasn't needed, but it was still a surgery. And so, it began that conversation again for a bunch of people to say, you know, what could I do? What could I tolerate? What would I accept in terms of risk and potential benefit? Dr Jones: Well, I think that's a great overview of a disorder where, you know, I think the neurologist's role is really indispensable. Right? I mean, you have to have this conversation not just once, this is a conversation that you have over time. And again, I really want to refer our listeners to this article. It's just a fantastic overview of a common disorder, but one where I think there are probably gaps where we can improve care. And Dr Shih, I want to thank you for joining us, and thank you for such a great discussion on essential tremor. I learned a lot from your article, and I learned even more from the interview today. I suspect our readers and listeners will too. Dr Shih: Well, thank you again for the invitation and the opportunity to kind of spread the word on this really common condition. Dr Jones: Again, we've been speaking with Dr Ludy Shih, author of a fantastic article on essential tremor in Continuum's latest issue on movement disorders. Please check it out, and thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

Charles was living a full life when Parkinson's disease hit. Although a progressive neurodegenerative disease affecting movement, there are many medical treatments available to help with symptom management. While Levadopa, the standard of care treatment helped Charles with his symptoms of tremor, he was unable to tolerate it due to the extreme Restless Legs Syndrome he developed. Deep Brain Stimulation (DBS) surgery and treatment at the Movement Disorders Center at Pacific Neuroscience Institute, has saved his life and put him on a new trajectory full of movement and joy. Learn more.

Katie Fagan, Senior Program Coordinator & Clinical Social Worker at Northwestern University Parkinson’s Disease and Movement Disorders Center, joins Lisa Dent to talk about Northwestern Medicine patients performing at Second City’s Improv for People with Parkinson's Disease and their Care Partners tomorrow at 3 pm. For more information or to register, visit nm.org or email […]

Black and African American people diagnosed with Parkinson's disease (PD) face disparities in healthcare access and outcomes, potentially leading to decreased access to care, resources, and research opportunities. It is crucial to recognize their unique needs and experiences so that scientists can better understand how PD impacts diverse communities. The Parkinson's Foundation aims to identify these healthcare disparities to better serve and support the community. In this first episode of our Black History Month special, Kimberly Gamble, Program Coordinator at Atrium Health, and Lance Wilson, Licensed Social Worker and Center Coordinator at Jefferson Health's Comprehensive Parkinson's Disease and Movement Disorders Center, share real-life examples of outreach strategies that they have used when engaging with the Black and African American community to dispel common misconceptions about research studies, and emphasize the importance of representing and showing up for your community.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we comprised some of the most interesting conversations from Mind Moments podcast episodes in 2023, highlighting research in neurology that moves the field forward. The NeurologyLive team included several reaction episodes to FDA approved medicines, providing clinicians an overview of what they can expect from these new therapies and how they will be used in clinic going forward. Those included in this week's episode, in order of appearance, are: Sharon Cohen, MD, FRCPC, behavioral neurologist and medical director of the Toronto Memory Program at the University of Toronto, and a trial investigator for Clarity AD, the phase 3 trial of lecanemab. Check out the full episode here: https://www.neurologylive.com/view/special-episode-lecanemab-approved-for-alzheimer-disease Robert A. Hauser, MD, MBA, director of the Parkinson's and Movement Disorders Center at the University of South Florida.Check out the full episode here: https://www.neurologylive.com/view/episode-81-widening-therapeutic-window-parkinson-disease Alberto Espay, MD, PhD, the division director and Research Endowed Chair of the James J. and Joan A. Gardner Family Center for Parkinson's Disease and Movement Disorders, and a professor of clinical neurology and rehabilitation medicine at the University of Cincinnati.Check out the full episode here: https://www.neurologylive.com/view/episode-94-discussion-leqembi-lecanemab-approval-alzheimer-disease Carolina Ferreira Atuesta, MD, MSc, a scientific researcher and clinical data manager at the Icahn School of Medicine at Mount Sinai.Check out the full episode here: https://www.neurologylive.com/view/episode-82-managing-seizures-after-ischemic-stroke Natalie Goedeker, CPNP, a nurse practitioner in neurology in the Neuromuscular Division at Washington University in St Louis.Check out the full episode here: https://www.neurologylive.com/view/special-episode-tofersen-approved-sod1-als Want more Mind Moments episodes? Click here for all of NeurologyLive®'s podcast episodes. Episode Breakdown: 1:20 – Cohen on the safety of lecanemab, including the 3 patient deaths reported in the supportive clinical trial program.  6:25 – Hauser on the clinical advantages of IPX203, a potential new carbidopa/levodopa formulation for patients with Parkinson disease.  9:20 – Espay on tempering expectations of lecanemab and other antiamyloid therapies in the treatment of Alzheimer disease. 13:20 – Atuesta on the lack of standardized methods for monitoring patients with poststroke seizures, including elders. 17:00 – Goedeker on the approval of gene therapy SRP-9001 for patients with Duchenne muscular dystrophy, the integration process, and safety considerations clinicians should be aware of. This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com. Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Identifying Parkinson's disease early and starting a treatment plan can go a long way in delaying the onset of disability or loss of function. Once that diagnosis is made, supportive care and planning become crucial parts of managing the disease. Dr. Bernardo Rodrigues, director of UConn Health's Parkinson's Disease and Movement Disorders Center, explains. (May 2023, Dr. Bernardo Rodrigues, Chris DeFrancesco) Parkinson's Disease and Movement Disorders Center at UConn Health https://health.uconn.edu/parkinsons/ Call for appointment: 860-679-4888 Dr. Bernardo Rodrigues https://facultydirectory.uchc.edu/profile?profileId=Rodrigues-Bernardo Parkinson's disease patient support group at UConn Health https://health.uconn.edu/parkinsons/patient-resources/ Parkinson's disease caregiver support group at UConn Health parkinsons@uchc.edu, 860-679-3224

Join us for a live and interactive discussion with a leader in treatment of movement disorders Parkinson disease is the second most neurodegenerative disease, after Alzheimer disease, that affects up to two million Americans, the overwhelming majority of whom are aged 60 and older.  Dr. Drew Falconer is board certified in neurology and is a fellowship-trained movement disorders specialist. He serves as Medical Director Inova Parkinson's and Movement Disorders Center.  www.ipmdc.org Find a specialist

In this episode, physiotherapist Josefa Domingos MSc and PhD Candidate and speech language pathologist John Dean MA CCC-SLP discuss dual task training for Parkinsons and how you can implement dual task training to address cognitive domains: attention, executive function, working memory and visual spatial.  They discuss the programs they developed both in person and online, including the Lisbon Falls Trampoline Training program.  Physiotherapist Josefa Domingos MSc and PhD Candidate and speech language pathologist John Dean MA CCC-SLP are clinicians specializing in Parkinson's and related disorders. Since 2011, the duo has been collaborating on their approach to Dual Task Exercise for Parkinson's, combining movement, voice, and cognition, with multiple publications on their approach, training programs for clinicians in the EU and the US, and countless hours of classes and clinical work, both online and in-person.  Currently, they can be found online with the Inova Parkinson and Movement Disorders Center, The Parkinson's Foundation of Western Pennsylvania and the Parkinson Association of the Rockies, among others. They also volunteer with a number of US and international organizations, including the International Parkinson's and Movement Disorder Society, the World Parkinson's Coalition, The Davis Phinney Foundation, and Parkinson's Europe. Resources: Dual Task for ParkinsonsParkinson's Europe ExerciseCastVirtual Classes:Dual Task for Parkinson's: Exercise to improve movement, voice & cognition:  Every Monday and Wednesday from 3:00 pm – 4:00 pmZumba Gold for PD: Every Tuesday and Thursday at 1:00 pm (EST). RECENTLY DIAGNOSED BOOT CAMP: 3RD TUESDAY OF EACH MONTH FROM 2:3O – 4:00 PM (EST) 8-part “Exercise Pizza” Series: Week 8 – Thursday, April 27: “Speech Recognition Challenge” (12:30-1:30 MST)Articles: Community Exercise: A New Tool for Personalized Parkinson's Care or Just an Addition to Formal Care? - PMC (nih.gov)A Novel Boot Camp Program to Help Guide Personalized Exercise in People with Parkinson Disease - PMC (nih.gov) An Online Dual-Task Cognitive and Motor Exercise Program for Individuals With Parkinson Disease (PD3 Move Program): Acceptability Study - PMC (nih.gov)Lisbon Intensive Falls Trampoline Training (LIFTT) Program for people with Parkinson's for balance, gait, and falls: study protocol for a randomized controlled trial - PMC (nih.gov)Is Being Physically Active Enough or Do People with Parkinson's Disease Need Structured Supervised Exercise? Lessons Learned from COVID-19 - PMC (nih.gov)

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Robert A. Hauser, MD, MBA, director of the Parkinson's and Movement Disorders Center at the University of South Florida. He spoke about the current state of therapeutics in Parkinson disease (PD), some of the lingering challenges in day-to-day management, the promise of novel agents in development such as IPX203, and more. Looking for more movement disorder discussion? Check out the NeurologyLive® movement disorder clinical focus page, or for more PD-focused content, check out our disease spotlight on Parkinson disease. Episode Breakdown: 1:20 – Lingering unmet needs in Parkinson disease management 3:10 – The advances in identifying therapeutic targets in PD 4:25 – Bridging the gap to more effective long-term treatment 6:00 – Overview of IPX203 and its potential to treat PD 7:45 – Neurology News Minute 10:15 – Possible advantages of IPX203 13:25 – Safety profile of IPX203 in clinical development 15:50 – The importance of addressing dose-wearing off 16:40 – Closing thoughts This episode is brought to you by the Giants of Multiple Sclerosis®. This premier neuroscience award program celebrates pioneers, innovators, and future generations of leaders for their remarkable achievements in Multiple Sclerosis. Nominations close January 31, 2023! Nominate: neurologylive.com/Giants-of-MS The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Neurelis Files IND for Potential First Therapy to Treat Cerebral Cavernous Malformations CDC and FDA Announce Stroke Safety Concern Related to Pfizer-BioNTech Bivalent COVID-19 Vaccine FDA Hands Eli Lilly Complete Response Letter for Donanemab After Lack of Long-Term Data FDA Clears Trial Hold on Late-Onset Pompe Disease Gene Therapy AT845 Proclaim XR Spinal Cord Stimulation Wins Approval for Painful Diabetic Peripheral Neuropathy Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Get answers to the questions that you and your colleagues have asked! In this episode, Jonathan M. Meyer, MD; Leslie Citrome, MD, MPH; and Stuart Isaacson, MD, provide answers to audience questions that were submitted at recent CCO Psychiatry meetings. Their thoughtful responses cover your questions on screening, communicating with patients, medication management, and more. Moderators Rajesh Pahwa, MD; Charles DeBattista, DMH, MD; and Greg W. Mattingly, MD, provide complementary commentary throughout the question and answer session, adding interprofessional perspective to the activity.Presenters:Leslie Citrome, MD, MPHClinical ProfessorDepartment of Psychiatry and Behavioral SciencesNew York Medical CollegeValhalla, New YorkCharles DeBattista, DMH, MDChiefDepression Research ClinicDirectorMedical Student Education in PsychiatryProfessor of Psychiatry and Behavioral SciencesStanford University School of MedicineStanford, CaliforniaStuart Isaacson, MDDirectorParkinson's Disease and Movement Disorders Center of Boca RatonBoca Raton, FloridaClinical Associate Professor of NeurologyFIU Herbert Wertheim College of MedicineMiami, FloridaGreg W. Mattingly, MDAssociate Clinical ProfessorPsychiatryWashington University School of MedicineSt Louis, MissouriPresidentSt Charles Psychiatry AssociatesSt Charles, MissouriJonathan M. Meyer MDVoluntary Clinical Professor, Department of PsychiatryUniversity of California, San DiegoPsychopharmacology ConsultantBalboa Naval Medical Center First Episode Psychosis ProgramState of Nevada Project ECHO First Episode Psychosis ProgramRajesh Pahwa, MDChief, Parkinson and Movement Disorder DivisionDirector, Parkinson Foundation Center of ExcellenceUniversity of Kansas Medical CenterKansas City, KansasFor more programs in this series, visit: https://bit.ly/3Bg0oTv

During this episode, I talk with Dr. Jenna Renfroe (she/her) about the importance of business ownership, neuropsychology and how to optimizing brain health. Jenna is board-certified in clinical neuropsychology by the American Board of Professional Psychology. She received her doctoral training at the University of Florida (Go Gators!) in Clinical and Health Psychology with a specialization in Clinical Neuropsychology and then completed an internship in Clinical Neuropsychology and Rehabilitation Psychology at the VA Boston Healthcare System, through Harvard Medical School and the Boston University School of Medicine. Jenna completed a two-year post-doctoral fellowship with the Movement Disorders Center of Excellence at the Medical University of South Carolina, Department of Neurology, Division of Neurosciences. ​ She has specialized training in the neuroscience of emotion, anxiety, and mindfulness. Jenna has a heart for veterans and works extensively with active duty and veteran members of the United States Armed Forces. One of the highlights of her career is ongoing work with an interdisciplinary team of experts that teaches resiliency and leadership skills to active duty military leaders through the 360 Program. ​ Above all, Jenna has a passion for helping others and connecting to the human spirit. She is determined to help people care for themselves better in early to middle adulthood, to stave off the negative effects of emotional and physical illness and continue to thrive throughout their lifespan.TOPICS IN THIS EPISODE:Baby steps in the beginning of business ownership – outsourcing and networking Authenticity and creating win-win networking relationship360 Program in working with Veterans What the heck is Neuropsychology and how can therapists work with these practitioners for the benefit of our clients Tips to optimize brain healthNeurotransmitters and your gutBenefits of diet, exercise and sleepOFFERS & HELPFUL LINKS:·       Jenna's website ·       Jennifer Agee coaching page·       Counseling Community Facebook community·       Counseling Community Instagram·       Alaskan Cruise: Experiential Therapeutic Intervention Training for Therapists June 3-10, 2023·       Cabo, Mexico: Dreamer's Retreat for Entrepreneurial Therapists October 6-8, 2022

Essential tremor affects an estimated 10 million Americans and classically starts anytime between age 40-90, sometimes earlier. Join us for a live and interactive discussion with a leader in treatment of movement disorders. Dr. Drew Falconer is board certified in neurology and is a fellowship-trained movement disorders specialist. He serves as Medical Director Inova Parkinson's and Movement Disorders Center .

Most people with Parkinson's disease (PD) first seek medical care when they recognize or are troubled by symptoms – often stiffness, slowness of movement, or tremor. They may go on drug therapy at the time of diagnosis or, typically, within six to twelve months to relieve those symptoms.   In order for researchers and drug developers to test and ultimately find drugs that can slow the progression of the disease, they need to test those drugs in people who are not already on medications to alleviate symptoms and compare them to similar people taking a placebo. Currently there is no blood test or other biomarker to measure progression, so the most common and straightforward way for drug trials to judge progression is to observe signs and symptoms in people not receiving symptomatic medications such as levodopa, dopamine agonists, or other drugs that make symptoms less apparent.   Dr. Robert Hauser, Director of the Parkinson's Disease and Movement Disorders Center at the University of South Florida in Tampa, urges people early in the course of their disease to enter a clinical trial as soon as they receive a PD diagnosis and before they go on medication. The longer that they can be observed before taking a potential disease-modifying medication, the greater the ability of researchers to detect changes, or in the case of a drug in development, if successful, not to see changes. However, patients who can go up to a year without medication are in short supply, in part because patients often wait to seek medical help until they want medication. As Dr. Hauser wrote in a medical publication a few years ago, “… why see a doctor when you don't need treatment?”   But the answer is because people very early in the course of their disease are vital to finding drugs that can slow progression. Dr. Hauser terms the critical period of about one year between the time of first motor symptoms appearing to initiating symptomatic therapy the “Golden Year” for participation in disease modifying clinical trials. So, he wrote, “It is critical that care providers and patients don't unknowingly waste this golden year.” In this episode he lays out the problem, has messages for patients and providers, and tells how such a system of referral to entry into clinical trials can work.

Brought to US Healthcare professionals by Acorda Therapeutics  Dr. Salima Brillman, Director of the Parkinson's Disease and Movement Disorders Center of Silicon Valley, discusses the under treatment of OFF episodes in patients with Parkinson's disease.    Ahlskog JE, et al. Mov Disord. 2001;16(3):448-458., Armstrong MJ, et al. PLoS One.  2019;14(4):e0215384., Chou KL, et al. Parkinsonism Relat Disord. 2018;51:9-16., Connolly BS, et al. JAMA. 2014;311(16):1670-1683., Levit A, et al. Res Rev Parkinsonism. 2019;9:3-8., Olanow CW, et al. Neurology. 2009;72(21 Suppl 4):S1-136., Pahwa R, et al. Curr Med Res Opin. 2009;25(4):841-849., Rastgardani T, et al. Front. Neurol. 2019;10:892., Rastgardani T, et al. Mov Disord Clin Pract. 2018;5(5):461-470., Stacy M, et al. Mov Disord. 2005;20(6):726-733., Suarez-Cedeno G, et al. Parkinsons Dis. 2017;2017:9358153. 

As Parkinson’s disease (PD) progresses into its advanced stages, symptoms can become increasingly difficult to manage. At some point, the person with PD and care partners may consider hospice services, which can optimize the quality of life for the person and the family. Whether the person resides at home, in an assisted living facility, or in a nursing home, hospice can come to them. Hospice is really part of palliative care, which aims to relieve the burden of a disease not only near the end of life but all along its course. Both the terms “palliative care” and “hospice” are often misunderstood, and certain myths surround them.   This podcast is the first of a two-part series on hospice and palliative care. In this first episode, Jessica Shurer, MSW, LCSW, Clinical Social Worker and Center Coordinator of the Movement Disorders Center at the University of North Carolina at Chapel Hill, a Parkinson’s Foundation Center of Excellence, helps to dispel some of the misunderstanding about hospice. She describes what hospice is, how it operates, and when and how to consider it. Moreover, she highlights the medical, psychological, and logistical benefits it can bring to the person with PD and to care partners.

Movement Disorders Specialist, Dr. Drew Falconer, Co-Director, Inova Parkinson's and Movement Disorders Center in Fairfax, VA discusses the launch of Abbott's NeuroSphere™ Virtual Clinic, the first technology in the U.S. that allows patients to receive stimulation settings from their doctor without ever leaving their homes. This practice-changing advancement allows patients to remain safe from the COVID-19 pandemic, but still receive the essential care they need for pain or movement disorders. NeuroSphere Virtual Clinic can also help people who may have inadequate access to healthcare, urban or rural, giving them an alternate solution to traveling any distance and to receive much-needed care. The NeuroSphere Virtual Clinic is compatible with Abbott's suite of neuromodulation technologies. Dr. Drew Falconer is board certified in neurology and is a fellowship-trained movement disorders specialist. He joined Inova Neurology in 2015 with the launch of the Inova Parkinson's and Movement Disorders Center where he serves as Co-Medical Director. He specializes in advanced care of patients with Parkinson's disease, essential tremor, dystonia, Huntington's disease, tic disorders and other movement disorders. Dr. Falconer serves as assistant professor at the Virginia Commonwealth University School of Medicine, Inova Campus. He became interested in neurology and movement disorders after seeing the impact that quality, compassionate care combined with cutting-edge pharmacology and technology could have on a patient's condition. His goal is to work with his patients to restore the quality of life they deserve. He is additionally qualified in deep brain stimulation and botulinum toxin injections. A native of New Orleans, Dr. Falconer currently resides in McLean, VA, with his wife and two children. In his spare time, he enjoys cooking, spending time outdoors and LSU football. #NeuroSphere #Abott

In this episode you will meet Dr. Drew Falconer.  Dr. Falconer is board certified in neurology and is a fellowship-trained movement disorders specialist. He is the Director of the Inova Parkinson's and Movement Disorders Center and specializes in advanced care of patients with Parkinson's disease, essential tremor, dystonia, Huntington's disease, tic disorders and other movement disorders. He is uniquely qualified in the areas of deep brain stimulation (DBS) and botulinum toxin injections. Dr. Falconer speaks nationally on various topics in Movement Disorders and is a respected national educator in Parkinson's Disease and DBS.”During this episode Dr. Falconer discusses modern approaches to treatment, nonmedical musts, and Parkinson's during COVID.  Please join me on my next episode when I meet with the leadership team from Rock Steady Boxing in Indianapolis, Indiana.  Kristy Rose Follmar, Chris Timberlake, Dr. Ryan Cotton, and Keri Eisenberg share the history of Rock Steady Boxing, discuss research and exercise medicine and the future for Rock Steady Boxing.  See you Tuesday...(Feb. 23rd, 2021)

In this episode you will meet Molly Donelan.  Molly is the Director of Events and programs at Sportrock Climbing Center in Alexandria, Virginia where she has been working and climbing for over 12 years. Molly was able to combine her love of climbing as well as her passion for neuroscience when she started a Parkinson's climbing group at Sportrock 8 years ago. Molly discusses the benefits of rock climbing, why rock climbing is an especially good exercise for those with Parkinson's Disease and what she has learned from people living with Parkinson's.Please join me on my next episode with Dr. Draw Falconer.  Dr. Falconer is board certified in neurology and is a fellowship-trained movement disorders specialist. He is the Director of the Inova Parkinson's and Movement Disorders Center and specializes in advanced care of patients with Parkinson's disease as well as other movement disorders.  Dr. Falconer and I discuss current approaches to treatment, nonmedical musts, and Parkinsons during COVID.See you Tuesday....(Jan. 26, 2021)

Neurology wasn't Dr. Nisha Chhabria's first choice. She wanted to be an orthopedic surgeon, but her connection to Parkinson's disease and movement disorders led her on a path to helping people in Palm Beach County who suffer from tremors. We chat about how she's changing her patient's lives, the new medical breakthroughs in Parkinson's, and why this field of medicine is deeply personal for her. Listen to why Dr. Nisha Chhabria is one of the most dedicated People of Palm Beach. Link to Sound File for Sight Impaired: Click Here Host: Suzanne Boyd Producer: Jaime ("Jemmy") Legagneur, Chief Enthusiasm Officer Title Sponsor: Interested in becoming POPB's next Title Sponsor? Contact FPN today! Featured Photo Credit: Suzanne Boyd Guest: Dr. Nisha Chhabria from the Parkinson's Disease and Movement Disorders Center of Boca Raton Suzanne Boyd Productions: Stephanie Craig, Executive Producer Music Bed Courtesy of: Buffy Rose Follow People of Palm Beach on Facebook, Twitter, and Instagram. Additional Support Provided by: Florida Podcast Network, Little Smiles of Florida, Listeners Like You!! Partner with FPN: Become the Voice of YOUR Town!! From sponsoring episode segments through creating and growing your own branded show, we have the solution to promote you while we promote Florida! We are currently boarding shows to build out our network. And, you don’t want to miss ANY of the new hosts and podcasts were have joining us. Search for and subscribe to “Florida Podcast Network” on iTunes and all your favorite podcast players to get more of this and ALL our shows. Have a suggestion for the Network? Join us in the FPN Insiders group on Facebook and let us know!    FPN:  Check out the other shows on the Florida Podcast Network

Neurology wasn't Dr. Nisha Chhabria's first choice. She wanted to be an orthopedic surgeon, but her connection to Parkinson's disease and movement disorders led her on a path to helping people in Palm Beach County who suffer from tremors. We chat about how she's changing her patient's lives, the new medical breakthroughs in Parkinson's, and why this field of medicine is deeply personal for her. Listen to why Dr. Nisha Chhabria is one of the most dedicated People of Palm Beach. Link to Sound File for Sight Impaired: Click Here Host: Suzanne Boyd Producer: Jaime ("Jemmy") Legagneur, Chief Enthusiasm Officer Title Sponsor: Interested in becoming POPB's next Title Sponsor? Contact FPN today! Featured Photo Credit: Suzanne Boyd Guest: Dr. Nisha Chhabria from the Parkinson's Disease and Movement Disorders Center of Boca Raton Suzanne Boyd Productions: Stephanie Craig, Executive Producer Music Bed Courtesy of: Buffy Rose Follow People of Palm Beach on Facebook, Twitter, and Instagram. Additional Support Provided by: Florida Podcast Network, Little Smiles of Florida, Listeners Like You!! Partner with FPN: Become the Voice of YOUR Town!! From sponsoring episode segments through creating and growing your own branded show, we have the solution to promote you while we promote Florida! We are currently boarding shows to build out our network. And, you don’t want to miss ANY of the new hosts and podcasts were have joining us. Search for and subscribe to “Florida Podcast Network” on iTunes and all your favorite podcast players to get more of this and ALL our shows. Have a suggestion for the Network? Join us in the FPN Insiders group on Facebook and let us know!    FPN:  Check out the other shows on the Florida Podcast Network

How medical education is structured affects doctors in training, and thus, how they practice later on. Their level of experience with different diseases and conditions determines how they will be able to diagnose and treat the people who come to them for help. Given the relatively limited time for medical school and advanced training in light of the vast variety of diseases, medical educators have to be selective about what they require trainees to experience. A core curriculum gives medical students exposure to various medical specialties in their “rotations,” in which they spend several weeks at a time in one specialty area. Trainees have some leeway in what electives they wish to pursue beyond the core curriculum. As important as neurology is, often trainees are not required to take it, and some elect not to. Dr. Sagari Bette of the University of Miami Miller School of Medicine Parkinson’s Disease and Movement Disorders Center, a Parkinson’s Foundation Center of Excellence, says it is important for medical students to get a good foundation in neurology and movement disorders early in order for them to best care for people with Parkinson’s disease and other movement disorders once they are in practice. She explains how medical education is done now and proposes how it could be improved in the future, including the use of educational videos.

As people with Parkinson’s disease experience a variety of symptoms and challenges beyond movement problems, a comprehensive, team approach can benefit them with matters such as blood pressure drops, urinary symptoms, sleep disturbances, sexual and intimacy matters, and other quality of life issues affecting them and their caregivers. However, due to the associated stigma or potential feelings of embarrassment, people with PD may not bring these matters up with their clinicians. In this podcast, Dr. Tanya Gurevich, director of the Movement Disorders Center at Tel Aviv Medical Center in Israel, a Parkinson’s Foundation Center of Excellence, focuses on those problems that people with Parkinson’s often do not discuss with their care team but, for many of them, may have easy solutions.

More and more people are exploring medical marijuana, also called cannabis, as a treatment option for various chronic health conditions, including Parkinson’s disease. Several states have legalized medical cannabis, but because federal drug laws have prevented scientific investigations on cannabis and its components for many years, much is still unknown about its use for medical purposes. Patients have questions about it, and physicians are still feeling their way through the landscape of medicinal cannabis use. Dr. Danny Bega of Northwestern University’s Parkinson’s Disease and Movement Disorders Center in Chicago, a Parkinson’s Foundation Center of Excellence, sheds light on some of the issues and concerns surrounding the use of medicinal cannabis.

Alpha-synuclein is a protein in the human brain that is linked with the development of Parkinson’s disease. An important scientific paper came out in September 2017 describing how some common drugs, already approved by the Food and Drug Administration for other purposes, may lower the production of alpha-synuclein – and potentially protect against Parkinson’s. Dr. David K. Simon, Director of the Parkinson's Disease and Movement Disorders Center at Beth Israel Deaconess Medical Center in Boston, a Parkinson’s Foundation Center of Excellence, describes what the researchers did and what they found.

Physicians play a critical role in dysphagia management, even though swallowing may not have been included in their medical training. This installment of Down the Hatch features a conversation with Dr. Michael Okun, Department Chair of Neurology and Co-Director of the Movement Disorders Center of the University of Florida. We discuss the lack of training across medical disciplines in dysphagia as well as suggestions for how swallowing clinicians and researchers can advocate for improvements in dysphagia management. Get up! Stand up!

In this episode of the podcast, I interview Dr. Benzi Kluger - neurologist, Parkinson's researcher, Director of the Movement Disorders Center at the University of Colorado Hospital, and all-around great guy! Topics include: Dr. Kluger's background working with Parkinson's, advice for people newly diagnosed with the disease, information about the Movement Disorders Center, discussion of the new Palliative Care Clinic for Parkinson's that Dr. Kluger is running (as well as palliative care for Parkinson's more generally), and Dr. Kluger's thoughts on mindfulness as it relates to Parkinson's treatment - for those with the disease, as well as caregivers and health professionals.

PRE-RECORDED - TUESDAY, JUNE 17, 2014 Our incredible special guest is Claudia Testa, MD, PhD, Associate Professor of Neurology, and Associate Director of Clinical Research and medical director of the new VCU Parkinson's and Movement Disorders Center. The Center aims to integrate research, clinical care, and education and outreach missions in an interdisciplinary collaborative approach to making a difference in movement disorders. Dr. Testa moved to VCU in 2011, where she is excited to lead a new Huntington disease program. We will be discuss her career of care and research. Read more... After completing her MD and PhD degrees, Dr. Testa returned to Boston for internship at Beth Israel Hospital, then neurology residency in the Partners program at Massachusetts General Hospital and Brigham and Women's Hospital, where she was a chief resident her final year. She moved to Emory University for a movement disorders fellowship and basic research with Dr. Timothy Greenamyre. The HDSA Center of Excellence for Huntington Disease at Emory University was an important part of her growth as a clinician and scientist. Over eleven years at Emory she transitioned from fellow to faculty to medical director of the HDSA Center of Excellence, with involvement in several HSG studies. More recently, to enhance her skills in human disease based research she completed a Masters in Clinical and Translational Research (2012) while a faculty member at Emory University. Between Emory and VCU, she has over 13 years’ experience as an HD clinical study investigator, working with symptomatic, pre symptomatic, and HD at risk research participants. Her current research interests are in genetic causes and risks for essential tremor, Huntington disease pre-motor physiology changes, and Huntington disease observational and treatment trials.

TUESDAY, JUNE 17, 2014 Our incredible special guest is Claudia Testa, MD, PhD, Associate Professor of Neurology, and Associate Director of Clinical Research and medical director of the new VCU Parkinson's and Movement Disorders Center. The Center aims to integrate research, clinical care, and education and outreach missions in an interdisciplinary collaborative approach to making a difference in movement disorders. Dr. Testa moved to VCU in 2011, where she is excited to lead a new Huntington disease program. We will be discuss her career of care and research. Read more... After completing her MD and PhD degrees, Dr. Testa returned to Boston for internship at Beth Israel Hospital, then neurology residency in the Partners program at Massachusetts General Hospital and Brigham and Women's Hospital, where she was a chief resident her final year. She moved to Emory University for a movement disorders fellowship and basic research with Dr. Timothy Greenamyre. The HDSA Center of Excellence for Huntington Disease at Emory University was an important part of her growth as a clinician and scientist. Over eleven years at Emory she transitioned from fellow to faculty to medical director of the HDSA Center of Excellence, with involvement in several HSG studies. More recently, to enhance her skills in human disease based research she completed a Masters in Clinical and Translational Research (2012) while a faculty member at Emory University. Between Emory and VCU, she has over 13 years’ experience as an HD clinical study investigator, working with symptomatic, pre symptomatic, and HD at risk research participants. Her current research interests are in genetic causes and risks for essential tremor, Huntington disease pre-motor physiology changes, and Huntington disease observational and treatment trials.

Wednesday, August 8, 2012 In direct response to previous shows and information disseminated about the AAN (the American Academy of Neurology) guidelines for treating chorea in Huntington's, Melissa Armstrong, MD, MSc and Gary Gronseth, MD, FAAN are here today to explain how the AAN Clinical Practice Guideline process works to deliver the best evidence-based recommendations to physicians who are treating for neurological disorders, in particular Huntington's disease.  About the AAN The American Academy of Neurology (AAN), established in 1948, is an international professional association of more than 25,000 neurologists and neuroscience professionals dedicated to promoting the highest quality patient-centered neurologic care. Gary S Gronseth, MD, FAAN Dr. Gronseth is a Professor of Neurology at the University of Kansas and has been involved with patient care and medical education for 25 years. Dr Gronseth is also the evidence-based medicine (EBM) methodologist for the American Academy of Neurology (AAN). He oversees many EBM projects of the AAN including the development of clinical practice guidelines for 18 years. Melissa J Armstrong, MD, MSc Dr. Armstrong is an Assistant Professor of Neurology at the University of Maryland School of Medicine is fellowship-trained in movement disorders and has a master's degree in health care research from the University of Toronto. She cares for patients at the University of Maryland Parkinson's Disease and Movement Disorders Center, participates in medical research and has been involved in guideline development for the American Academy of Neurology (AAN) since 2006, first as an author and now also as a member of the Guideline Development Subcommittee. www.aan.com 

Host: Anthony Alessi, MD Guest: Lisa Shulman Would it be better for Parkinson's patients to meet with their doctor in a group setting? Group visits are among the the novel approaches being studied for Parkinson's patients. Dr. Lisa Shulman, professor of neurology and co-director of the Maryland Parkinson's Disease and Movement Disorders Center in Baltimore, joins host Dr. Anthony Alessi to discuss who might benefit from group visits, how it compares to traditional care, and the practical billing issues involved. They also discuss new research on treadmill walking in the treatment of patients with Parkinson's disease. Produced in cooperation with:

This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Interim Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Michael Benatar interview Dr. John Ravits about his paper on ALS motor phenotype heterogeneity, focality and spread. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about foreign accent syndrome. The podcast concludes where Dr. Alberto Espay interviews Dr. Octavian Adam for the Lesson of the Week segment about the Resident & Fellow Section paper on patient telephone calls in a Movement Disorders Center. The participants had nothing to disclose except for Drs. Ravits and Espay.Dr. Ravits serves as an editorial board member of Amyotrophic Lateral Sclerosisand Other Motor Neuron Disorders and the Journal of Neurodegeneration andRegeneration; is funded by a research program development grant from Microsoft Research and private non-profit foundation grants from the Juniper Foundation, the Wyco Foundation, the Moyer Foundation, and the Benaroya Foundation; and received past research support from the NIH [#NS051738 (PI)] and the Department of Defense [#USAMRAA W81XWH-07-0246 (sub-PI)].Dr. Espay received has personal compensation as a consultant for Boehringer Ingelheim; grant support from Codman; Medtronic, Inc; Allergan, Inc.; and CleveMed, and honoraria from UCB-SCHWARZ PHARMA AG; Medtronic, Inc. and Novartis.

Guest: Matthew B. Stern, MD Host: Jennifer Shu, MD, FAAP Medication and physical therapy have been mainstay treatments for controlling neurologic symptoms associated with Parkinson's disease. One strategy for mitigating the characteristic tremors, rigidity and slow movement has focused on deep brain stimulation (DBS). What are the risks and benefits of this surgical intervention, when is it indicated, and how does it compare with medical treatment for Parkinson's? Host Dr. Jennifer Shu welcomes Dr. Matthew Stern, the Parker Family Professor of Neurology and director of the Parkinson's Disease and Movement Disorders Center at the University of Pennsylvania School of Medicine, to explore DBS and its indication for your patients with Parkinson's disease. Dr. Stern also offers his view on the question of whether DBS could eventually be considered for treatment much earlier in the disease's progression, or potentially as a first-line therapy for patients with Parkinson's.

Guest: Matthew B. Stern, MD Host: Jennifer Shu, MD Medication and physical therapy have been mainstay treatments for controlling neurologic symptoms associated with Parkinson's disease. One strategy for mitigating the characteristic tremors, rigidity and slow movement has focused on deep brain stimulation (DBS). What are the risks and benefits of this surgical intervention, when is it indicated, and how does it compare with medical treatment for Parkinson's? Host Dr. Jennifer Shu welcomes Dr. Matthew Stern, the Parker Family Professor of Neurology and director of the Parkinson's Disease and Movement Disorders Center at the University of Pennsylvania School of Medicine, to explore DBS and its indication for your patients with Parkinson's disease. Dr. Stern also offers his view on the question of whether DBS could eventually be considered for treatment much earlier in the disease's progression, or potentially as a first-line therapy for patients with Parkinson's.